FY2030 Earnings Forecast for RCUS Issued By HC Wainwright

Arcus Biosciences, Inc. (NYSE:RCUS) – HC Wainwright issued their FY2030 earnings estimates for shares of Arcus Biosciences in a research note issued on Thursday, February 26th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of $0.30 per share for the year. HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.22. Arcus Biosciences had a negative return on equity of 69.86% and a negative net margin of 142.91%.The company had revenue of $33.00 million for the quarter, compared to the consensus estimate of $24.94 million. During the same quarter last year, the business posted ($1.03) earnings per share. The firm’s revenue was down 8.3% compared to the same quarter last year.

Several other research analysts have also commented on RCUS. The Goldman Sachs Group raised Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $16.00 to $28.00 in a report on Monday, January 12th. Wall Street Zen cut shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a research report on Monday, December 15th. Wells Fargo & Company set a $23.00 target price on shares of Arcus Biosciences and gave the stock an “equal weight” rating in a research report on Thursday, February 12th. Finally, Bank of America raised their price target on Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.33.

Arcus Biosciences Price Performance

Shares of NYSE RCUS opened at $19.53 on Friday. The stock’s 50-day simple moving average is $21.60 and its two-hundred day simple moving average is $18.36. Arcus Biosciences has a twelve month low of $6.50 and a twelve month high of $26.40. The firm has a market capitalization of $2.11 billion, a P/E ratio of -5.92 and a beta of 0.84. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22.

Insider Buying and Selling at Arcus Biosciences

In other news, CAO Alexander Azoy sold 4,343 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $22.25, for a total transaction of $96,631.75. Following the transaction, the chief accounting officer directly owned 18,531 shares of the company’s stock, valued at approximately $412,314.75. This trade represents a 18.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Richard Markus sold 4,494 shares of Arcus Biosciences stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total value of $99,587.04. Following the completion of the transaction, the insider owned 65,647 shares in the company, valued at approximately $1,454,737.52. This represents a 6.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 263,987 shares of company stock valued at $6,025,620. 9.60% of the stock is currently owned by insiders.

Institutional Trading of Arcus Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its stake in shares of Arcus Biosciences by 17.5% during the fourth quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock valued at $77,000 after purchasing an additional 482 shares during the period. Amalgamated Bank raised its holdings in Arcus Biosciences by 3.9% during the 3rd quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock valued at $266,000 after buying an additional 736 shares during the last quarter. Creative Planning raised its holdings in Arcus Biosciences by 2.7% during the 3rd quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after buying an additional 771 shares during the last quarter. Hantz Financial Services Inc. boosted its position in Arcus Biosciences by 121.9% during the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after buying an additional 881 shares during the period. Finally, New York State Teachers Retirement System grew its holdings in Arcus Biosciences by 1.1% in the 4th quarter. New York State Teachers Retirement System now owns 92,431 shares of the company’s stock worth $2,203,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.